A comparison of nafarelin acetate and danazol in the treatment of endometriosis.
Nafarelin 400 micrograms daily and danazol 600 mg daily were compared in a double-blind randomized study. Eighty-two patients with endometriosis were treated for 6 months after an initial laparoscopy and 74 had a second laparoscopy. Twenty-two (30%) patients had complete disease regression, 42 (57%) patients had a partial regression, and in 10 (13%) patients disease was unchanged or worse. Both treatments led to significant regression of active disease but not of adhesions. At 3 months follow-up, 34 (64%) patients reported their symptoms were improved, 15 (28%) reported no change, and 4 (8%) were worse. Nafarelin was associated with more hot flushes and headaches, and danazol with more weight gain. No significant differences, however, were noted in treatment efficacy between the two groups.
Kennedy
S H
SH
John Radcliffe Hospital, Oxford, United Kingdom.
Williams
I A
IA
Brodribb
J
J
Barlow
D H
DH
Shaw
R W
RW
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D000704:Analysis of Variance; D003613:Danazol / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004715:Endometriosis / Q000188:drug therapy*; D004958:Estradiol / Q000096:biosynthesis; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D017274:Nafarelin; D011245:Pregnadienes / Q000627:therapeutic use*; D000267:Tissue Adhesions / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy*
D011245:Pregnadienes; D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D003613:Danazol